About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2025 Clareo Health. All rights reserved.

WITHDRAWNPhase 2

Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC

A Phase II, Multi-center, Single Arm, Open Label Study to Assess Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer

NCT02672358•Novartis Pharmaceuticals

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Non-Small-Cell Lung Cancer

Interventions

Dabrafenib

Trametinib

Key Dates

Start Date

September 3, 2018

Primary Completion Date

September 2, 2019

Completion Date

December 7, 2020

Last Updated

August 10, 2018

Related Studies

RECRUITINGPhase 2

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

NCT07336732

Non-Small-Cell Lung Cancer

RECRUITINGPhase 2

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

NCT05568212

Non-small-cell Lung Cancer Patients

RECRUITINGPhase 2

Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

NCT06574347

Non-Small-Cell Lung Cancer

RECRUITINGPhase 2/3

Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer

NCT02448992

Non-Small-Cell Lung Cancer (NSCLC)Brain Metastasis

Enrolling By InvitationPhase 3

Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.

NCT06281964

Non-Small-Cell Lung Cancer

Active Not RecruitingPhase 1/2

AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer

NCT05904379

Advanced Non-small-cell Lung Cancer

View all related studies

Sponsors

Lead Sponsor

Novartis Pharmaceuticals

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 10, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions